Clinical Trials for Celldex Therapeutics

Explore 14 clinical trials worldwide

Showing 1-14 of 14 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Celldex Therapeutics

Clinical Trials (14)

NCT06727552
A Study of Barzolvolimab in Patients With Atopic Dermatitis
PHASE2Recruiting
120 participants
Started: Jan 7, 2025 · Completed: May 31, 2027
1 condition1 sponsor39 locations
NCT06650761
A Phase I Study of CDX-622
PHASE1Recruiting
80 participants
Started: Nov 1, 2024 · Completed: Apr 30, 2026
1 condition1 sponsor1 location
NCT06455202
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
PHASE3Recruiting
915 participants
Started: Jul 19, 2024 · Completed: Apr 30, 2027
1 condition1 sponsor241 locations
NCT06445023
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
PHASE3Recruiting
915 participants
Started: Jul 11, 2024 · Completed: Apr 30, 2027
1 condition1 sponsor230 locations
NCT06366750
A Study of Barzolvolimab in Patients With Prurigo Nodularis
PHASE2Recruiting
120 participants
Started: Apr 12, 2024 · Completed: Jun 30, 2026
1 condition1 sponsor69 locations
NCT05231122
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
PHASE2Recruiting
80 participants
Started: Mar 12, 2024 · Completed: Dec 30, 2026
15 conditions4 sponsors2 locations
NCT05774184
A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
PHASE2Active, not recruiting
86 participants
Started: Jun 1, 2023 · Completed: Dec 31, 2025
1 condition1 sponsor45 locations
NCT05349890
Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
PHASE1Active, not recruiting
1 participants
Started: Apr 3, 2023 · Completed: Apr 15, 2028
1 condition3 sponsors1 location
NCT05405660
A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
PHASE2Active, not recruiting
196 participants
Started: Jun 28, 2022 · Completed: Sep 30, 2025
1 condition1 sponsor76 locations
NCT05029999
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
PHASE1Recruiting
30 participants
Started: Apr 20, 2022 · Completed: Apr 20, 2026
2 conditions4 sponsors7 locations
NCT04930783
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
PHASE1Recruiting
30 participants
Started: Jan 3, 2022 · Completed: Sep 30, 2030
2 conditions2 sponsors1 location
NCT03688178
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
PHASE2Active, not recruiting
43 participants
Started: Aug 26, 2020 · Completed: Mar 31, 2026
1 condition2 sponsors1 location
NCT03804944
Converting HR+ Breast Cancer Into an Individualized Vaccine
PHASE2Recruiting
100 participants
Started: Mar 17, 2020 · Completed: Dec 31, 2027
1 condition4 sponsors8 locations
NCT03789097
Vaccination With Flt3L, Radiation, and Poly-ICLC
PHASE1/PHASE2Recruiting
56 participants
Started: Apr 5, 2019 · Completed: Mar 31, 2025
3 conditions3 sponsors1 location